OptiBiotix Health PLC Presentation of abstract at conference
May 03 2017 - 2:01AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
03 May 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentation of abstract at Probiotics and Prebiotics
conference
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skin care, announces that it has had
an abstract accepted for presentation at the International
Scientific Conference on Probiotics and Prebiotics in Budapest,
Hungary from 20 - 22 June 2017 (IPC2017). IPC2017 is the largest
scientific conference worldwide focusing on probiotics and
prebiotics for scientists, researchers, product developers,
industry and the investment community. The conference attracts up
to 500 leading scientists, opinion leaders, investors, and
clinicians from more than 80 countries.
The abstract, titled "The Development of a Targeted Synergistic
Synbiotic for Lactobacillus plantarum LP(LDL) (R)", describes how
by combining its OptiScreen(R) and OptiBiotic(R), OptiBiotix were
able to synthesise a dietary fibre that substantially enhances the
cholesterol reducing activity of LP(LDL) (R) in gut models. This
creates the potential for next generation LP(LDL) (R) products with
cholesterol reduction levels potentially approaching those of
statins.
Commenting, Stephen O'Hara, CEO of OptiBiotix said: "This
abstract demonstrates the ability of OptiBiotix to create targeted
prebiotics which when combined with a probiotic greatly enhances
the probiotics growth and biological effect, in this case
cholesterol reduction. This new research highlights the potential
for the development of species or genera-specific probiotics to
selectively enhance the growth and health benefits of existing
probiotics. This has the potential to provide improved next
generation products with enhanced performance and product
differentiation in the probiotics functional food market, a market
that is expected to be worth in excess of $46.5bn by 2020."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZLLFBDEFLBBK
(END) Dow Jones Newswires
May 03, 2017 02:01 ET (06:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024